NM |
Manufacturer |
Size |
Suspended media |
Aerosol generation method |
Exposure route |
Reference |
AgNP |
NANATECH Co, Korea |
60 nm (52.7-70.9) |
0.5% Carboxy methyl cellulose |
NA |
Oral |
[20] |
AgNP |
NANOTECH Co, Korea |
CMD 56 nm GSD 1.46 |
0.5% Carboxy methylcellulose |
NA |
Oral |
[22] |
AgNP |
ABC Nanotech, Korea, OECD WPMN reference material |
CMD 10 nm GSD 1.28 |
0.9% citrate |
NA |
Oral |
[21] |
AgNP |
ABC Nanotech, Korea, OECD WPMN reference material |
CMD 25 nm |
0.9% citrate |
NA |
oral |
[21] |
AgNP |
Daedeok Science, Korea |
CMD 18 nm |
Aerosol |
Evaporation and condensation from silver wire |
Inhalation |
[24] |
AgNP |
INEXUS INC, Korea |
CMD 18.1-19.6 |
Aerosol |
Evaporation and condensation from silver wire |
Inhalation |
[23] |
AgNP |
ABC Nanotech, Korea, OECD WPMN reference material |
CMD 10 nm GSD 1.28 |
0.9% citrate |
MA |
intravenous |
[25,26] |
Table 1: Nanoparticle identification
NM, nanomaterial; AgNP, silver nanoparticle; NA, not applicable
AgNP size |
Route of |
Duration |
Dose/Conc |
Blood Agconc (?/g) |
platelet |
PT |
APTT |
Toxicity |
Ref |
60 |
Oral/MF |
28-d |
0, 30, 300, 1000 mg/kg |
M: 0.01, 0.18, 0.43, 0.80 |
|
- |
Shortening in the high dose (1000 mg/kg/d in female rats |
Liver toxicity from 300 mg/kg |
[20] |
56 |
Oral/MF |
90-d |
0, 30, 125, 500 mg/kg |
M: 0.001, 0.111, 0.191, 0.419 |
|
- |
- |
Liver toxicity from 125 mg/kg |
[22] |
10 |
Oral/MF |
28-d |
0, 100, 500 mg/kg |
M: 0, 0.17, 0.27 |
|
- |
- |
- |
[21] |
25 |
Oral/ |
28-d |
0, 100, 500 mg/kg |
M: 0, 0.11, 0.31 |
Decreased at 500 mg/kg female rats after 2-month recovery |
Increased in the high dose |
- |
- |
[21] |
18 |
Inhalation |
90-d/MF |
0, 49, 133,, 515 ?/m3 |
M: 0.00009, 0.00068, 0.0018, 0.0043 |
|
|
- |
Liver toxicity and lung inflammation from 515 ?/m3;; increased percent of erythrocyte aggregation in the high concentration female |
[24] |
18.1-19.6 |
Inhalation |
28-d. PEO-28/M |
0.31, 82, 116 ?/m3 |
ND |
|
|
decreased significantly after 28-day exposure at all concentrations |
Lung inflammation from 82 ?/m3 |
[23] |
10 |
IV injection |
28-d/M |
0, 10, 100 µg/kg/d |
M: 0, 0.0016, 0.0016 |
|
|
- |
- |
[25,26] |
Table 2:Subacute and subchronic toxicity studies on nanomaterials with platelet coagulation data.
AgNP, silver nanoparticles; AuNP gold nanoparticles; conc, concentration; PT, prothrombin time; APTT, activated partial thromboplastine time; M, male; F, female; SD, Sprague-Dawley; IV, intravenous; *AgNP and AuNP mixed; 1 = reliable without restriction; 2 =reliable with restriction; PEO, post-exposure observation
Data quality |
OECD WPMN Category |
GLP compliance |
Based on OECD test guidelines |
Peer-review publication |
High |
1or 2 |
Yes |
Yes |
Yes |
Medium |
1 or 2 |
No |
Yes/no |
Yes/no |
Low |
4 |
No |
No |
No |
Table 3:Data quality criteria
1 = reliable without restriction; 2 =reliable with restriction
Tables at a glance